WO2008102777A1 - インスリン抵抗性改善剤 - Google Patents

インスリン抵抗性改善剤 Download PDF

Info

Publication number
WO2008102777A1
WO2008102777A1 PCT/JP2008/052767 JP2008052767W WO2008102777A1 WO 2008102777 A1 WO2008102777 A1 WO 2008102777A1 JP 2008052767 W JP2008052767 W JP 2008052767W WO 2008102777 A1 WO2008102777 A1 WO 2008102777A1
Authority
WO
WIPO (PCT)
Prior art keywords
cpsf5
cpsf6
substance
insulin resistance
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052767
Other languages
English (en)
French (fr)
Inventor
Hideki Kizawa
Shoji Fukusumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to EP08711588A priority Critical patent/EP2123303A1/en
Priority to CA002678757A priority patent/CA2678757A1/en
Priority to JP2009500195A priority patent/JPWO2008102777A1/ja
Priority to US12/449,671 priority patent/US20100029561A1/en
Publication of WO2008102777A1 publication Critical patent/WO2008102777A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

　本発明は、CPSF5タンパク質の発現もしくは活性を阻害する物質、および／またはCPSF6タンパク質の発現もしくは活性を阻害する物質を含有してなるインスリン抵抗性改善剤、糖代謝異常が関与する疾患の予防・治療剤を提供する。該物質として、(a) CPSF5（もしくはCPSF6）をコードする核酸に対するアンチセンス核酸、(b) CPSF5（もしくはCPSF6）をコードするRNAに対するsiRNA、(c) CPSF5（もしくはCPSF6）をコードするRNAに対するsiRNAを生成し得る核酸などが提供される。さらに、CPSF5および／またはCPSF6を産生する細胞を用いたインスリン抵抗性改善物質のスクリーニング法が提供される。
PCT/JP2008/052767 2007-02-20 2008-02-19 インスリン抵抗性改善剤 Ceased WO2008102777A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08711588A EP2123303A1 (en) 2007-02-20 2008-02-19 Ameliorating agent for insulin resistance
CA002678757A CA2678757A1 (en) 2007-02-20 2008-02-19 Ameliorating agent for insulin resistance
JP2009500195A JPWO2008102777A1 (ja) 2007-02-20 2008-02-19 インスリン抵抗性改善剤
US12/449,671 US20100029561A1 (en) 2007-02-20 2008-02-19 Ameliorating agent for insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-039947 2007-02-20
JP2007039947 2007-02-20

Publications (1)

Publication Number Publication Date
WO2008102777A1 true WO2008102777A1 (ja) 2008-08-28

Family

ID=39710052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052767 Ceased WO2008102777A1 (ja) 2007-02-20 2008-02-19 インスリン抵抗性改善剤

Country Status (5)

Country Link
US (1) US20100029561A1 (ja)
EP (1) EP2123303A1 (ja)
JP (1) JPWO2008102777A1 (ja)
CA (1) CA2678757A1 (ja)
WO (1) WO2008102777A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010706A1 (ja) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21シスエレメント結合物質

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724381B2 (en) * 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2025230463A1 (en) * 2024-05-03 2025-11-06 Agency For Science, Technology And Research In vitro hepatic glucose production assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076939A2 (en) * 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
WO2005118865A2 (en) * 2004-05-28 2005-12-15 St. Jude Children's Research Hospital Diagnosis and treatment of drug resistant leukemia
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
WO2006082390A1 (en) * 2005-02-01 2006-08-10 The University Court Of The University Of Glasgow Materials and methods for diagnosis and treatment of chronic fatigue syndrome
US20070031841A1 (en) * 2001-02-28 2007-02-08 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
JP2007039947A (ja) 2005-08-02 2007-02-15 Sumitomo Rubber Ind Ltd 制振シートおよび水槽

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085436A1 (en) * 2003-07-08 2005-04-21 Hao Li Method to treat conditions associated with insulin signalling dysregulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031841A1 (en) * 2001-02-28 2007-02-08 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
WO2005076939A2 (en) * 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
WO2005118865A2 (en) * 2004-05-28 2005-12-15 St. Jude Children's Research Hospital Diagnosis and treatment of drug resistant leukemia
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
WO2006082390A1 (en) * 2005-02-01 2006-08-10 The University Court Of The University Of Glasgow Materials and methods for diagnosis and treatment of chronic fatigue syndrome
JP2007039947A (ja) 2005-08-02 2007-02-15 Sumitomo Rubber Ind Ltd 制振シートおよび水槽

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
"Enzyme Immonoassay", 1978, IGAKUSHOIN
"Enzyme Immonoassay", 1982, IGAKUSHOIN
"Enzyme Immonoassay", 1987, IGAKUSHOIN
"Immunochemical Techniques", ACADEMIC PRESS PUBLISHING
"Immunochemical Techniques", vol. 121
"Immunochemical Techniques", vol. 73
"Immunochemical Techniques", vol. 74
"Immunochemical Techniques", vol. 84
"Immunochemical Techniques", vol. 92
"Radioimmunoassay", 1974, KODANSHA LTD.
"Saibo Kogaku", vol. 8, 1995, article "Shin Saibo Kogaku Jikken Protocol", pages: 263 - 267
"Sequel to the Radioimmunoassay", 1979, KODANSHA LTD.
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310
FRIEDMAN, J.E. ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 31475 - 31481
GENOME BIOL., vol. 6, 2005, pages R100
IMANISHI, T. ET AL., CHEM. COMMUN., 2002, pages 1653 - 9
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS
JEPSEN, J.S. ET AL., OLIGONUCLEOTIDES, vol. 14, 2004, pages 130 - 46
KARLIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
KOBAYASHI T. ET AL.: "Changes in aortic endothelial gene expressions and relaxation responses following chronic short-term insulin treatment in diabetic rats", ATHEROSCLEROSIS, vol. 185, no. 1, 2006, pages 47 - 57, XP025242459 *
KRAINER, A.R: "Eukaryotic mRNA Processing", 1997, IRL (OXFORD UNIVERSITY) PRESS
KUBO, T. ET AL., NUCLEIC ACIDS RES., vol. 34, 2006, pages 6264 - 6271
METHODS IN ENZYMOLOGY, vol. 70
MILLEVOI, S. ET AL., EMBO J., vol. 25, 2006, pages 4854 - 4864
MORITA, K. ET AL., NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS, vol. 22, 2003, pages 1619 - 21
MYERS; MILLER, CABIOS, vol. 4, 1988, pages 11 - 17
NATURE, vol. 411, no. 6836, 2001, pages 494 - 498
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
NUCLEIC ACIDS RES., vol. 29, no. 13, 2001, pages 2780 - 2788
NUCLEIC ACIDS RES., vol. 34, 2006, pages 6264
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 - 2448
PROC. NATL. ACAD. SCI. USA, vol. 98, no. 10, 2001, pages 5572 - 5577
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
PUIGSERVER, P. ET AL., NATURE, vol. 423, 2003, pages 550 - 555
RUEGSEGGER ET AL., MOL. CELL, vol. 1, 1998, pages 243 - 253
SALTIEL, A.R., CELL, vol. 104, 2001, pages 517 - 529
SAMUEL, V.T. ET AL., DIABETES, vol. 55, 2006, pages 2042 - 2050
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 308, 2005, pages 1164
STOILOV, P. ET AL., DNA CELL BIOL., vol. 21, 2002, pages 803 - 818
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
VIROLOGY, vol. 52, 1973, pages 456
VIROLOGY, vol. 8, 1959, pages 396

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010706A1 (ja) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21シスエレメント結合物質

Also Published As

Publication number Publication date
EP2123303A1 (en) 2009-11-25
CA2678757A1 (en) 2008-08-28
JPWO2008102777A1 (ja) 2010-05-27
US20100029561A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
WO2007137156A3 (en) Rnai modulation of aha and therapeutic uses thereof
WO2008028686A3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2012046084A3 (en) Short rna molecules
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2011046983A3 (en) Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2007115168A8 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2010036918A3 (en) Intracellular dna receptor
WO2010033915A9 (en) Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
WO2007134161A8 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2007140000A3 (en) Administration of the reg1 anticoagulation system
NZ593365A (en) Pharmaceutical preparation comprising a blood mononuclear cell culture
WO2004072248A3 (en) A process for delivering sirna to cardiac muscle tissue
WO2009135165A3 (en) Small humanin-like peptides
WO2009086428A3 (en) Methods and compositions for increasing gene expression
WO2005079532A3 (en) Methods and compositions for enhancing risc activity in vitro and in vivo
IL174633A (en) A cell containing a nucleic acid encoding a gamma-carboxylation protein, a method for producing gamma-carboxylation protein, a gamma-protein carboxylation produced by this method, pharmaceutical preparations and the use of such a gamma-carboxylation protein as a drug
WO2008102777A1 (ja) インスリン抵抗性改善剤
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2011133584A8 (en) Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A3 (en) Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2010004584A3 (en) Process for production of anti-diabetic compound in root culture of catharanthus roseus
WO2005021776A3 (en) METHODS OF USING MAMMALIAN RNase H AND COMPOSITIONS THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711588

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009500195

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008711588

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449671

Country of ref document: US

Ref document number: 2678757

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE